Ownership Capital B.V. Decreases Stake in DexCom, Inc. (NASDAQ:DXCM)

Ownership Capital B.V. cut its stake in DexCom, Inc. (NASDAQ:DXCM) by 7.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 701,971 shares of the medical device company’s stock after selling 59,839 shares during the period. DexCom accounts for about 2.0% of Ownership Capital B.V.’s portfolio, making the stock its 20th largest position. Ownership Capital B.V. owned about 0.18% of DexCom worth $54,592,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. Blue Whale Capital LLP lifted its stake in shares of DexCom by 91.9% during the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after buying an additional 113,000 shares during the period. Taylor Frigon Capital Management LLC grew its stake in DexCom by 51.6% during the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after purchasing an additional 11,075 shares during the last quarter. Brooktree Capital Management purchased a new stake in DexCom during the 3rd quarter valued at about $683,000. National Pension Service increased its holdings in shares of DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after purchasing an additional 37,363 shares during the period. Finally, Intact Investment Management Inc. purchased a new position in shares of DexCom in the third quarter worth about $650,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on DXCM shares. Leerink Partners cut their price target on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. JPMorgan Chase & Co. boosted their target price on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Citigroup increased their price target on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Finally, StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $99.06.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $89.68 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a market cap of $35.03 billion, a PE ratio of 62.71, a PEG ratio of 2.31 and a beta of 1.14. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The firm has a fifty day moving average of $83.06 and a 200 day moving average of $75.85.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, research analysts predict that DexCom, Inc. will post 1.98 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,083 shares of company stock valued at $3,309,794 over the last quarter. 0.30% of the stock is currently owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.